ABSTRACT
Purpose To test the ability of convolutional neural networks (CNNs) to effectively capture the intensity, shape, and texture properties of tumors as defined by standardized radiomic features.
Methods Standard 2D and 3D CNN architectures with an increasing number of convolutional layers (up to 9) were trained to predict the values of 16 standardized radiomic features from synthetic images of tumors, and tested. In addition, several ImageNet-pretrained state-of-the-art networks were tested. The synthetic images replicated the quality of real PET images. A total of 4000 images were used for training, 500 for validation, and 500 for testing.
Results Radiomic features quantifying tumor size and intensity were predicted with high accuracy, while shape irregularity features had very high prediction errors and generalized poorly between training and test sets. For example, mean normalized prediction error of tumor diameter (mean intensity) with a 5-layer 2D CNN was 4.23 ± 0.25 (1.88 ± 0.07), while the error for tumor sphericity was 15.64 ± 0.93. Similarly-high error values were found with other shape irregularity and heterogeneity features, both with standard and state-of-the-art networks.
Conclusions Standard CNN architectures and ImageNet-pretrained advanced networks have a significantly lower capacity to capture tumor shape and heterogeneity properties compared to other features. Our findings imply that CNNs trained end-to-end for clinical outcome prediction and other tasks may under-utilize tumor shape and texture information. We hypothesize, that to improve CNN performance, these radiomic features can be computed explicitly and added as auxiliary variables to the dense layers in the networks, or as additional input channels.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (NIH) / Canadian Institutes of Health Research (CIHR) Quantitative Imaging Network (QIN) Grant number 137993, and in part through computational resources and services provided by Microsoft and the Vice President Research and Innovation at the University of British Columbia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UBC-BC Cancer Research Ethics Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study contained protected patient health information and are only available under the respective IRBs. Parts of data not covered by IRBs can be made available upon request.
